ASTRAZEN.NS Живые сигналы | Максимизируйте прибыль с Getagraph.com

Live Chart Being Loaded With Signals

Commentary (6 май 2024 @ 13:00):

AstraZeneca Pharma India Limited, a biopharmaceutical company, manufactures, distributes, and markets pharmaceutical products in India and internationally...

Stats
Объем за сегодня	10 944.00
Средний объем	22 237.00
Рыночная капитализация	135.48B
EPS	INR0 ( 2024-02-08 )
Дата следующего отчета о доходах	( INR0 ) 2024-05-28
Last Dividend	INR16.00 ( 2023-07-14 )
Next Dividend	INR0 ( N/A )
P/E	97.75
ATR14	INR3.40 (0.06%)

Объем Корреляция

Длинно: 0.05 (neutral)

Кратко: -0.92 (very strong negative)

Signal:(40.674) Neutral

AstraZeneca Pharma India Корреляция

10 Самые положительные корреляции
SEYAIND.NS	0.834

10 Самые отрицательные корреляции
CONTROLPR.NS	-0.807

Вы знали?

Корреляция - это статистический показатель, описывающий связь между двумя переменными. Он изменяется от -1 до 1, где -1 указывает на идеальную отрицательную корреляцию (при увеличении одной переменной другая уменьшается), 1 указывает на идеальную положительную корреляцию (при увеличении одной переменной другая увеличивается), а 0 указывает на отсутствие корреляции (между переменными нет связи).

Корреляцию можно использовать для анализа связи между любыми двумя переменными, не только акциями. Она широко используется в таких областях, как финансы, экономика, психология и т. д.

AstraZeneca Pharma India Корреляция - Валюта/Сырье

-0.31
( neutral )

-0.39
( neutral )

-0.58
( weak negative )

-0.27
( neutral )

0.48
( neutral )

0.52
( weak )

AstraZeneca Pharma India Финансовые показатели

Annual	2022
Выручка:	INR10.03B
Валовая прибыль:	INR5.45B (54.37 %)
EPS:	INR39.72

FY	2022
Выручка:	INR10.03B
Валовая прибыль:	INR5.45B (54.37 %)
EPS:	INR39.72

FY	2022
Выручка:	INR8.06B
Валовая прибыль:	INR4.48B (55.63 %)
EPS:	INR24.60

FY	2021
Выручка:	INR8.09B
Валовая прибыль:	INR4.78B (59.12 %)
EPS:	INR37.30

Financial Reports:

No articles found.

AstraZeneca Pharma India Dividends

(Q3/22)	(Q4/22)	(Q1/23)	(Q2/23)	(Q3/23)	(Q4/23)	(Q1/24)	(Q2/24)	(Q3/24)	(Q4/24)
INR8.00 (N/A)	INR0 (N/A)	INR0 (N/A)	INR0 (N/A)	INR16.00 (N/A)	INR0 (N/A)	INR0 (N/A)	INR0 (N/A)	INR0 (N/A)	INR0 (N/A)

AstraZeneca Pharma India Dividend Information - Dividend Junior

Dividend Sustainability Score: 4.66 - low (54.78%) | Divividend Growth Potential Score: 2.22 - Decrease likely (55.56%)

Very Unsafe

High risk of being cut

Unsafe

Heightened risk of being cut

Borderline

Moderate risk of being cut

Safe

Unlikely to be cut

Very Safe

Very unlikely to be cut

Information

First Dividend	INR3.70	2003-04-17
Last Dividend	INR16.00	2023-07-14
Next Dividend	INR0	N/A
Payout Date	0000-00-00
Next Payout Date	N/A
# dividends	16	--
Total Paid Out	INR184.10	--
Avg. Dividend % Per Year	0.19%	--
Score	1.47	--
Div. Sustainability Score	4.66
Div.Growth Potential Score	2.22
Div. Directional Score	3.44	--

Next Divdend (Est)
(2024-09-25)

INR18.37 Estimate 2.96 %

Dividend Stability

0.24 Very Poor

Dividend Score

1.47

Pay Frequency

Sporadic

Yearly Payout

Year	Amount	Yield
2003	INR0	0.00%
2004	INR0	0.00%
2005	INR0	0.00%
2006	INR0	0.00%
2007	INR0	0.00%
2008	INR0	0.00%
2009	INR0	0.00%
2010	INR0	0.00%
2011	INR0	0.00%
2012	INR0	0.00%
2013	INR0	0.00%
2014	INR0	0.00%
2015	INR0	0.00%
2016	INR0	0.00%
2017	INR0	0.00%
2018	INR0	0.00%
2019	INR1.000	0.07%
2020	INR2.00	0.08%
2021	INR2.00	0.04%
2022	INR8.00	0.26%
2023	INR16.00	0.48%
2024	INR0	0.00%

Dividend Commentary

The company's low Dividend Sustainability Score (DSS) highlights potential challenges in upholding its current dividend levels. Unfortunately, its low Dividend Growth Potential Score (DGPS) suggests limited prospects for dividend growth. In conclusion, a more vigilant stance is recommended given the company's tentative dividend landscape.

Top 10 dividend Companies for NSE

Symbol	Title	Last dividend	Frequency	Years Dividend	Yearly Dividend
SUNDARMHLD.NS	Dividend Junior	2023-07-03	Annually	7	1.35%
NATIONALUM.NS	Dividend Knight	2023-09-15	Semi-Annually	26	4.12%
HLEGLAS.NS	Dividend Junior	2023-09-21	Annually	4	0.19%
CANTABIL.NS	Dividend Junior	2023-09-15	Annually	5	0.63%
RITES.NS	Dividend Knight	2023-09-08	Quarterly	7	3.95%
LAMBODHARA.NS	Dividend Junior	2023-09-14	Annually	10	0.87%
FORCEMOT.NS	Dividend Junior	2023-09-21	Annually	6	0.45%
APLAPOLLO.NS	Ex Dividend Junior	2023-09-01	Sporadic	13	0.07%
TATVA.NS	Dividend Junior	2023-09-08	Annually	3	0.04%
NUCLEUS.NS	Dividend Junior	2023-07-07	Annually	22	1.41%

Dividend Sustainability Score (DSS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
netProfitMarginTTM	0.116	1.500	7.67	10.00	[0 - 0.5]
returnOnAssetsTTM	0	1.200	0	0	[0 - 0.3]
returnOnEquityTTM	0.224	1.500	8.62	10.00	[0.1 - 1]
payoutRatioTTM	0	-1.000	0	0	[0 - 1]
currentRatioTTM	0	0.800	-5.00	-4.00	[1 - 3]
quickRatioTTM	0	0.800	-4.71	-3.76	[0.8 - 2.5]
cashRatioTTM	0	1.500	-1.111	-1.667	[0.2 - 2]
debtRatioTTM	0	-1.500	0	0	[0 - 0.6]
interestCoverageTTM	128.03	1.000	10.00	10.00	[3 - 30]
operatingCashFlowPerShareTTM	9.89	2.00	6.70	10.00	[0 - 30]
freeCashFlowPerShareTTM	9.89	2.00	5.06	10.00	[0 - 20]
debtEquityRatioTTM	0	-1.500	0	0	[0 - 2.5]
grossProfitMarginTTM	0.518	1.000	4.71	4.71	[0.2 - 0.8]
operatingProfitMarginTTM	0.145	1.000	9.10	9.10	[0.1 - 0.6]
cashFlowToDebtRatioTTM	0	1.000	-1.111	-1.111	[0.2 - 2]
assetTurnoverTTM	0	0.800	-3.33	-2.67	[0.5 - 2]
Total Score				4.66

Dividend Growth Score (DGS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
peRatioTTM	97.15	1.000	0.288	0	[1 - 100]
returnOnEquityTTM	0.224	2.50	9.11	10.00	[0.1 - 1.5]
freeCashFlowPerShareTTM	9.89	2.00	6.70	10.00	[0 - 30]
dividendYielPercentageTTM	0.296	1.500	2.61	0	[0 - 0.4]
operatingCashFlowPerShareTTM	9.89	2.00	6.70	10.00	[0 - 30]
payoutRatioTTM	0	1.500	0	0	[0 - 1]
pegRatioTTM	-2.86	1.500	-10.00	0	[0.5 - 2]
operatingCashFlowSalesRatioTTM	0.0207	1.000	-1.984	0	[0.1 - 0.5]
Total Score				2.22

AstraZeneca Pharma India

AstraZeneca Pharma India Limited, a biopharmaceutical company, manufactures, distributes, and markets pharmaceutical products in India and internationally. It manufactures and sells cardiovascular disease and diabetes medicines under the Brilinta, Betaloc, Crestor, Forxiga, Imdur, Kombiglyze XR, Onglyza, Seloken XL, Xigduo XR, and QTERN brands; Respiratory medicines under the Symbicort and FASENRA brand names; and oncology medicines under the LYNPARZA, Tagrisso, Iressa, Calquence, Casodex, Faslodex, Zoladex, and Arimidex brands. The company also offers products in the areas of renal, metabolic, and immunology diseases. It also provides clinical trial services. The company was incorporated in 1979 and is based in Bengaluru, India. AstraZeneca Pharma India Limited is a subsidiary of AstraZeneca Pharmaceuticals AB.